Drug Trial Radar · NCT06235125
Safety and Feasibility of Intraoperative Visualization With Cytalux in Children
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Apr 8, 2024
Primary completion
Nov 1, 2027
Study completion Nov 1, 2027
Sponsor
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of ChicagoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- On Target Laboratories, LLC
- First posted
- Jan 31, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Pediatric subjects aged 6-17 with biopsy confirmed cancer and imaging findings suspicious for pulmonary metastatic disease scheduled to undergo pulmonary metastasectomy via and open or minimally invasive approach.
Conditions
- Osteosarcoma
- Pulmonary Metastasis
- Fluorescence
- Metastatic Sarcoma
- Pediatrics
Interventions
CytaluxDrug
Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sensitivity of Near-infrared (NIR) imaging after pafolacianine injection for metastatic nodule identificationTime frame: 1 day
- False-Positive Rate of Near-infrared (NIR) imaging after pafolacianine injection for metastatic nodule identificationTime frame: 1 day
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ann & Robert H. Lurie Children's Hospital
Chicago, Illinois · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.